MTOR and acute lymphoblastic leukemia: These findings qualify FLT3, PI3K/mTOR and MEK1/2 inhibitors as alternative therapeutic agents for B-NEG ALL patients, especially in adults/elderly who frequently suffer of comorbidities and often cannot undergo intensive chemotherapeutic approaches.